Home / Health / Hormone Therapy Supply Chain Under Strain
Hormone Therapy Supply Chain Under Strain
17 Jun
Summary
- Oral progesterone supplies are strained, impacting fertility and menopause treatments.
- Demand for HRT surged after FDA safety warning removal in late 2025.
- Compounded medications pose risks due to lack of strict regulatory oversight.
U.S. supplies of oral progesterone are experiencing intermittent shortages, impacting patients undergoing fertility and menopause treatments. These supply concerns arise as demand for hormone replacement therapy (HRT) has surged since the FDA removed a significant safety warning in late 2025.
Prescriptions for progesterone-containing HRT have more than tripled since January 2021. Manufacturers report increased demand, with some working to expand production capacity. However, the U.S. Department of Health and Human Services notes one manufacturer faces delays while others have available product.
While these progesterone shortages are generally milder than those affecting estrogen patches, some patients still face prescription delays. Clinicians express caution about compounded progesterone and estrogen, warning that these preparations may not adhere to strict regulatory processes, potentially leading to inaccurate dosages and health issues.
